Patents by Inventor Todd R. Klaenhammer

Todd R. Klaenhammer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9980992
    Abstract: Methods and compositions for treating or preventing inflammatory disorders are provided. The compositions of the invention comprise a recombinant bacterium genetically modified to decrease the display of lipoteichoic acid on the cell surface. Methods of the invention comprise administering to a subject a recombinant bacterium modified to decrease the display of lipoteichoic acid on the cell surface. Administration of the recombinant bacterium promotes a desired therapeutic response. The recombinant bacterium may be administered in a single dose or series of doses. Methods of the invention find use in treating or preventing a variety of inflammatory disorders including, for example, treating or preventing inflammatory bowel disease, colitis, or Crohn's disease.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: May 29, 2018
    Assignees: Northwestern University, North Carolina State University
    Inventors: Todd R. Klaenhammer, Erika Pfeiler, Mansour Mohamadzadeh
  • Publication number: 20160324905
    Abstract: Methods and compositions for treating or preventing inflammatory disorders are provided. The compositions of the invention comprise a recombinant bacterium genetically modified to decrease the display of lipoteichoic acid on the cell surface. Methods of the invention comprise administering to a subject a recombinant bacterium modified to decrease the display of lipoteichoic acid on the cell surface. Administration of the recombinant bacterium promotes a desired therapeutic response. The recombinant bacterium may be administered in a single dose or series of doses. Methods of the invention find use in treating or preventing a variety of inflammatory disorders including, for example, treating or preventing inflammatory bowel disease, colitis, or Crohn's disease.
    Type: Application
    Filed: April 13, 2016
    Publication date: November 10, 2016
    Applicants: North Carolina State University, Northwestern University
    Inventors: Todd R. Klaenhammer, Erika Pfeiler, Mansour Mohamadzadeh
  • Patent number: 9340792
    Abstract: Methods and compositions for treating or preventing inflammatory disorders are provided. The compositions of the invention comprise a recombinant bacterium genetically modified to decrease the display of lipoteichoic acid on the cell surface. Methods of the invention comprise administering to a subject a recombinant bacterium modified to decrease the display of lipoteichoic acid on the cell surface. Administration of the recombinant bacterium promotes a desired therapeutic response. The recombinant bacterium may be administered in a single dose or series of doses. Methods of the invention find use in treating or preventing a variety of inflammatory disorders including, for example, treating or preventing inflammatory bowel disease, colitis, or Crohn's disease.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: May 17, 2016
    Assignees: North Carolina State University, Northwestern University
    Inventors: Todd R. Klaenhammer, Erika Pfeiler, Mansour Mohamadzadeh
  • Patent number: 9040302
    Abstract: Methods and compositions for targeted delivery of biotherapeutics are provided. The compositions comprise bile-sensitive St. thermophilus bacteria modified to release a biotherapeutic agent following bile exposure. Biotherapeutic agents released by the St. thermophilus bacteria disclosed herein include AQ and AQR rich peptides. Methods of the invention comprise administering to a subject a St. thermophilus bacterium modified to release a biotherapeutic agent following bile exposure. Administration of the St. thermophilus bacterium promotes a desired therapeutic response. The bacterium may be modified to express and release AQ or AQR rich peptides which subsequently inhibit cellular apoptosis or reduce mucosal damage. Thus, methods of the invention find use in treating or preventing a variety of gastrointestinal disorders including C. difficile infection and antibiotic-associated diarrhea.
    Type: Grant
    Filed: May 19, 2011
    Date of Patent: May 26, 2015
    Assignees: North Carolina State University, University of Virginia Patent Foundation
    Inventors: Todd R. Klaenhammer, Richard L. Guerrant, Glynis L. Kolling, Evelyn Durmaz, Michael P. Timko, Cirle Alcantara Warren
  • Publication number: 20130287810
    Abstract: The present invention relates to vaccine compositions and uses thereof. Embodiments of the present invention provide oral bacterial (e.g., probiotic lactic acid bacteria) vaccine delivery systems comprising an antigen and a dendritic cell-targeting peptide. Such compositions target vaccines to dendritic cells, resulting in a high level of humoral and acquired immunity, including both mucosal and systemic immunity. Such delivery systems find use in the specific delivery of a wide variety of oral vaccines to subjects.
    Type: Application
    Filed: January 18, 2013
    Publication date: October 31, 2013
    Applicant: NORTHWESTERN UNIVERSITY
    Inventors: Mansour Mohamadzadeh, Todd R. Klaenhammer
  • Publication number: 20130259834
    Abstract: Methods and compositions for targeted delivery of biotherapeutics are provided. The compositions comprise bile-sensitive St. thermophilus bacteria modified to release a biotherapeutic agent following bile exposure. Biotherapeutic agents released by the St. thermophilus bacteria disclosed herein include AQ and AQR rich peptides. Methods of the invention comprise administering to a subject a St. thermophilus bacterium modified to release a biotherapeutic agent following bile exposure. Administration of the St. thermophilus bacterium promotes a desired therapeutic response. The bacterium may be modified to express and release AQ or AQR rich peptides which subsequently inhibit cellular apoptosis or reduce mucosal damage. Thus, methods of the invention find use in treating or preventing a variety of gastrointestinal disorders including C. difficile infection and antibiotic-associated diarrhea.
    Type: Application
    Filed: May 19, 2011
    Publication date: October 3, 2013
    Applicants: UNIVERSITY OF VIRGINIA PATENT FOUNDATION, NORTH CAROLINA STATE UNIVERSITY
    Inventors: Todd R. Klaenhammer, Richard L. Guerrant, Glynis L. Kolling, Evelyn Durmaz, Michael P. Timko, Cirle Alcantara Warren
  • Publication number: 20130224153
    Abstract: Methods and compositions for treating or preventing inflammatory disorders are provided. The compositions of the invention comprise a recombinant bacterium genetically modified to decrease the display of lipoteichoic acid on the cell surface. Methods of the invention comprise administering to a subject a recombinant bacterium modified to decrease the display of lipoteichoic acid on the cell surface. Administration of the recombinant bacterium promotes a desired therapeutic response. The recombinant bacterium may be administered in a single dose or series of doses. Methods of the invention find use in treating or preventing a variety of inflammatory disorders including, for example, treating or preventing inflammatory bowel disease, colitis, or Crohn's disease.
    Type: Application
    Filed: June 16, 2011
    Publication date: August 29, 2013
    Applicants: NORTHWESTERN UNIVERSITY, NORTH CAROLINA STATE UNIVERSITY
    Inventors: Todd R. Klaenhammer, Erika Pfeiler, Mansour Mohamadzadeh
  • Publication number: 20120196325
    Abstract: Carbohydrate utilization-related and multidrug transporter nucleic acids and polypeptides, and fragments and variants thereof, are disclosed in the current invention. In addition, carbohydrate utilization-related and multidrug transporter fusion proteins, antigenic peptides, and anti-carbohydrate utilization-related and anti-multidrug transporter antibodies are encompassed. The invention also provides vectors containing a nucleic acid of the invention and cells into which the vector has been introduced. Methods for producing the polypeptides and methods of use for the polypeptides of the invention are further disclosed.
    Type: Application
    Filed: April 9, 2012
    Publication date: August 2, 2012
    Applicant: North Carolina State University
    Inventors: Todd R. Klaenhammer, Eric R. Altermann, Rodolphe Barrangou, W. Michael Russell, Tri Duong
  • Publication number: 20120149590
    Abstract: Cell wall, cell surface and secreted protein nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, cell wall, cell surface and secreted fusion proteins, antigenic peptides, and anti-cell wall, cell surface and secreted antibodies are encompassed. The invention also provides recombinant expression vectors containing a nucleic acid molecule of the invention and host cells into which the expression vectors have been introduced. Methods for producing the polypeptides of the invention and methods for their use are further disclosed.
    Type: Application
    Filed: November 19, 2007
    Publication date: June 14, 2012
    Applicant: North Carolina State University
    Inventors: Todd R. Klaenhammer, Eric Altermann, B. Logan Buck, W. Michael Russell
  • Patent number: 8178337
    Abstract: Carbohydrate utilization-related and multidrug transporter nucleic acids and polypeptides, and fragments and variants thereof, are disclosed in the current invention. In addition, carbohydrate utilization-related and multidrug transporter fusion proteins, antigenic peptides, and anti-carbohydrate utilization-related and anti-multidrug transporter antibodies are encompassed. The invention also provides vectors containing a nucleic acid of the invention and cells into which the vector has been introduced. Methods for producing the polypeptides and methods of use for the polypeptides of the invention are further disclosed.
    Type: Grant
    Filed: October 13, 2010
    Date of Patent: May 15, 2012
    Assignee: North Carolina State University
    Inventors: Todd R. Klaenhammer, Eric R. Altermann, Rodolphe Barrangou, W. Michael Russell, Tri Duong
  • Patent number: 7981651
    Abstract: Lactobacillus acidophilus NCFM nucleic acid molecules, polypeptides, fragments and variants thereof are provided in the current invention. In addition, fusion proteins, antigenic peptides, and antibodies are encompassed. The invention also provides recombinant expression vectors containing a nucleic acid molecule of the invention and cells comprising the expression vectors. Methods for producing the polypeptides of the invention and methods for their use are further provided.
    Type: Grant
    Filed: October 17, 2008
    Date of Patent: July 19, 2011
    Assignee: North Carolina State University
    Inventors: Todd R. Klaenhammer, Eric Altermann, Andrea Azcarate-Peril
  • Publication number: 20110151053
    Abstract: Protease-like nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, protease-like fusion proteins, antigenic peptides, and anti-protease-like antibodies are encompassed. The invention also provides vectors containing a nucleic acid molecule of the invention and cells into which the vectors have been introduced. Methods for producing the polypeptides and methods of use for the polypeptides of the invention are further disclosed.
    Type: Application
    Filed: January 20, 2011
    Publication date: June 23, 2011
    Applicant: North Carolina State University
    Inventors: Todd R. Klaenhammer, Eric Altermann, W. Michael Russell
  • Publication number: 20110091493
    Abstract: The present invention relates to vaccine compositions and uses thereof. Embodiments of the present invention provide oral bacterial (e.g., probiotic lactic acid bacteria) vaccine delivery systems comprising an antigen and a dendritic cell-targeting peptide. Such compositions target vaccines to dendritic cells, resulting in a high level of humoral and acquired immunity, including both mucosal and systemic immunity. Such delivery systems find use in the specific delivery of a wide variety of oral vaccines to subjects.
    Type: Application
    Filed: October 18, 2010
    Publication date: April 21, 2011
    Applicant: NORTHWESTERN UNIVERSITY
    Inventors: Mansour Moahamadzadeh, Todd R. Klaenhammer
  • Publication number: 20110081707
    Abstract: Carbohydrate utilization-related and multidrug transporter nucleic acids and polypeptides, and fragments and variants thereof, are disclosed in the current invention. In addition, carbohydrate utilization-related and multidrug transporter fusion proteins, antigenic peptides, and anti-carbohydrate utilization-related and anti-multidrug transporter antibodies are encompassed. The invention also provides vectors containing a nucleic acid of the invention and cells into which the vector has been introduced. Methods for producing the polypeptides and methods of use for the polypeptides of the invention are further disclosed.
    Type: Application
    Filed: October 13, 2010
    Publication date: April 7, 2011
    Applicant: North Carolina State University
    Inventors: Todd R. Klaenhammer, Eric Altermann, Rodolphe Barrangou, W. Michael Russell, Tri Duong
  • Patent number: 7897367
    Abstract: Protease-like nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, protease-like fusion proteins, antigenic peptides, and anti-protease-like antibodies are encompassed. The invention also provides vectors containing a nucleic acid molecule of the invention and cells into which the vectors have been introduced. Methods for producing the polypeptides and methods of use for the polypeptides of the invention are further disclosed.
    Type: Grant
    Filed: October 15, 2008
    Date of Patent: March 1, 2011
    Assignee: North Carolina State University
    Inventors: Todd R. Klaenhammer, Eric Altermann, W. Michael Russell
  • Publication number: 20110020900
    Abstract: Protease-like nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, protease-like fusion proteins, antigenic peptides, and anti-protease-like antibodies are encompassed. The invention also provides vectors containing a nucleic acid molecule of the invention and cells into which the vectors have been introduced. Methods for producing the polypeptides and methods of use for the polypeptides of the invention are further disclosed.
    Type: Application
    Filed: October 15, 2008
    Publication date: January 27, 2011
    Applicant: North Carolina State University
    Inventors: Todd R. Klaenhammer, Eric Altermann, W. Michael Russell
  • Publication number: 20110008292
    Abstract: Fructooligosaccharide (FOS)-related protein nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, FOS-related fusion proteins, antigenic peptides, and anti-FOS-related antibodies are encompassed. The invention also provides recombinant expression vectors containing a nucleic acid molecule of the invention and host cells into which the expression vectors have been introduced. Methods for producing the polypeptides of the invention and methods for their use are further disclosed.
    Type: Application
    Filed: September 23, 2010
    Publication date: January 13, 2011
    Applicant: North Carolina State University
    Inventors: Rodolphe Barrangou, Todd R. Klaenhammer, Eric Altermann
  • Patent number: 7838276
    Abstract: Carbohydrate utilization-related and multidrug transporter nucleic acids and polypeptides, and fragments and variants thereof, are disclosed in the current invention. In addition, carbohydrate utilization-related and multidrug transporter fusion proteins, antigenic peptides, and anti-carbohydrate utilization-related and anti-multidrug transporter antibodies are encompassed. The invention also provides vectors containing a nucleic acid of the invention and cells into which the vector has been introduced. Methods for producing the polypeptides and methods of use for the polypeptides of the invention are further disclosed.
    Type: Grant
    Filed: October 22, 2008
    Date of Patent: November 23, 2010
    Assignee: North Carolina State University
    Inventors: Todd R. Klaenhammer, Eric R. Altermann, Rodolphe Barrangou, W. Michael Russell, Tri Duong
  • Publication number: 20100279349
    Abstract: Stress-related nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, stress-related fusion proteins, antigenic peptides, and anti-stress-related antibodies are encompassed. The invention also provides recombinant expression vectors containing a nucleic acid molecule of the invention and cells into which the expression vectors have been introduced. Methods for producing the polypeptides and methods of use for the polypeptides of the invention are further disclosed.
    Type: Application
    Filed: April 30, 2010
    Publication date: November 4, 2010
    Applicant: NORTH CAROLINA STATE UNIVERSITY
    Inventors: TODD R. KLAENHAMMER, WILLIAM M. RUSSELL, ERIC ALTERMANN, ANDREA AZCARATE-PERIL
  • Patent number: 7824894
    Abstract: Fructooligosaccharide (FOS)-related protein nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, FOS-related fusion proteins, antigenic peptides, and anti-FOS-related antibodies are encompassed. The invention also provides recombinant expression vectors containing a nucleic acid molecule of the invention and host cells into which the expression vectors have been introduced. Methods for producing the polypeptides of the invention and methods for their use are further disclosed.
    Type: Grant
    Filed: July 2, 2008
    Date of Patent: November 2, 2010
    Assignee: North Carolina State University
    Inventors: Rodolphe Barrangou, Todd R. Klaenhammer, Eric Altermann